Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 11:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 80 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Buprenorphine or Placebo Clear all
Not listed Not applicable Interventional

Analgesic Response to Opioid Analgesics in Buprenorphine-Maintained Individuals

NCT02136784
View directory record Official record
Conditions
Analgesic Response
Interventions
morphine sulfate, hydrocodone, hydromorphone HCI, oxycodone, buprenorphine, oral tablet placebo, sublingual tablet placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
20 Years to 50 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Oct 10, 2026, 11:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid Users

NCT02413281
View directory record Official record
Conditions
Healthy
Interventions
ALKS 5461, Buprenorphine, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Oct 10, 2026, 11:18 PM EDT
Completed Phase 2 Interventional Results available

Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone

NCT00637000
View directory record Official record
Conditions
Opioid-related Disorders
Interventions
Buprenorphine soluble film, Buprenorphine/naloxone film strip, Placebo
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 10, 2026, 11:18 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Efficacy of Buprenorphine on Postoperative Endodontic Analgesia

NCT03268278
View directory record Official record
Conditions
Postoperative Pain
Interventions
Buprenorphine, Sterile saline, lidocaine, epinephrine (Local anesthetic)
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 10, 2026, 11:18 PM EDT
Completed Not applicable Interventional Results available

HIV, Buprenorphine, and the Criminal Justice System

NCT01550341
View directory record Official record
Conditions
Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, Opiate Addiction, Drug Dependence
Interventions
Buprenorphine/naloxone, Placebo Oral Tablet
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 10, 2026, 11:18 PM EDT
Completed Phase 1 Interventional

Phase 1 Study to Evaluate RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy Adults

NCT01046539
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
RDC-0313 + Buprenorphine, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 10, 2026, 11:18 PM EDT
Completed Phase 3 Interventional Results available

Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome

NCT01452789
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
sublingual buprenorphine, oral morphine
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
Not listed
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 10, 2026, 11:18 PM EDT
Withdrawn Phase 4 Interventional

Butrans for Treatment of Restless Legs Syndrome

NCT02138357
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
buprenorphine transdermal delivery system (BTDS), Placebo for BTDS patch
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 10, 2026, 11:18 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

BRIDGE Device for Treatment of Opioid Withdrawal

NCT04162145
View directory record Official record
Conditions
Opioid Withdrawal, Pain, Craving
Interventions
Active BRIDGE device placement, Inactive BRIDGE device placement
Device
Lead sponsor
BrightView LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Oct 10, 2026, 11:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Buprenorphine on Mood in Adults With a Range of Depressive Symptomatology

NCT02659787
View directory record Official record
Conditions
Depression
Interventions
0.2mg Buprenorphine, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 35 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 10, 2026, 11:18 PM EDT
Completed Early Phase 1 Interventional Results available

Galantamine and CBT4CBT Pilot to Prevent Relapse.

NCT03547622
View directory record Official record
Conditions
Methadone or Buprenorphine Detoxoxification
Interventions
MAT taper with galantamine, MAT taper with placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 19, 2022 · Synced Oct 10, 2026, 11:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and Ketoconazole

NCT01259115
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine transdermal patch, Ketoconazole tablet, Placebo to match ketoconazole tablet
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 54 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 10, 2026, 11:18 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Improving Treatment Outcomes for Prescription Opioid Dependence

NCT02543944
View directory record Official record
Conditions
Drug Dependence
Interventions
Gabapentin, Buprenorphine, Clonidine, Naltrexone (oral), Naltrexone (depot), Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 10, 2026, 11:18 PM EDT
Completed Phase 3 Interventional Results available

Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee

NCT00531427
View directory record Official record
Conditions
Chronic Pain, Osteoarthritis of the Knee
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
87
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 10, 2026, 11:18 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Buprenorphine HCl Buccal Film in Subjects With Low Back Pain

NCT01256450
View directory record Official record
Conditions
Pain, Low Back Pain
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 10, 2026, 11:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers

NCT01148537
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Buprenorphine transdermal patch, Matching placebo transdermal patch, Avelox (moxifloxacin hydrochloride) tablet
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 55 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 10, 2026, 11:18 PM EDT
Terminated Phase 2 Interventional Results available

Safety of Buprenorphine Transdermal System (BTDS) in Subjects With Acute Postoperative Pain After Total Knee Replacement

NCT00403234
View directory record Official record
Conditions
Postoperative Pain
Interventions
Buprenorphine transdermal patch, Placebo BTDS
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Phoenix, Arizona • San Clemente, California • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 10, 2026, 11:18 PM EDT
Completed Phase 3 Interventional Results available

Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL

NCT02696434
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Naltrexone, Placebo, Buprenorphine
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Lauderhill, Florida • Oakland Park, Florida • Winfield, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 10, 2026, 11:18 PM EDT
Terminated Phase 3 Interventional Results available

Buprenorphine Transdermal Patch in Subjects With Osteoarthritis Pain Requiring Opioids. Includes a 52-Week Safety Extension.

NCT00315458
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch, Placebo transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
48
States / cities
Birmingham, Alabama • Haleyville, Alabama • Muscle Shoals, Alabama + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 10, 2026, 11:18 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic & Pharmacodynamic Interaction of Lofexidine and Buprenorphine in Buprenorphine Maintained Patients

NCT01820442
View directory record Official record
Conditions
Opioid Dependence, Buprenorphine Withdrawal Syndrome
Interventions
Lofexidine HCl, Lofexidine-matching sugar pill
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 10, 2026, 11:18 PM EDT
Completed Phase 3 Interventional Results available

The Safety and Efficacy of the Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Back Pain.

NCT00315445
View directory record Official record
Conditions
Back Pain
Interventions
Buprenorphine transdermal patch, Placebo oxycodone/acetaminophen tablets, OXY/APAP, Placebo transdermal patch (TDS)
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1998
U.S. locations
12
States / cities
Huntsville, Alabama • Phoenix, Arizona • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 10, 2026, 11:18 PM EDT
Completed Phase 3 Interventional Results available

Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain

NCT02946073
View directory record Official record
Conditions
Chronic Lower Back Pain, Chronic Pain
Interventions
buprenorphine, Placebo
Drug · Other
Lead sponsor
Braeburn Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,053 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
69
States / cities
Birmingham, Alabama • Hamilton, Alabama • Vestavia Hills, Alabama + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 10, 2026, 11:18 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

True Functional Restoration and Analgesia in Non-Radicular Low Back Pain

NCT05419297
View directory record Official record
Conditions
Back Pain Lower Back Chronic, Chronic Pain
Interventions
Buprenorphine Buccal Film [Belbuca], Urine Drug Screening, actigraph, PROMIS 29, sit to stand test, numerical rating scale pain score, patient global impression of function, PROMIS - sleep
Drug · Other · Device + 1 more
Lead sponsor
Carolinas Pain Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 10, 2026, 11:18 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Buprenorphine Used With Treatment Resistant Depression in Older Adults

NCT02181231
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
venlafaxine XR, buprenorphine, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 10, 2026, 11:18 PM EDT